Disease · MONDO_0006515
acute pancreatitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. acute pancreatitis. Diseases, record MONDO_0006515. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006515
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Acute pancreatic inflammation, acute pancreatic necrosis, acute pancreatitis (disorder) [ambiguous], pancreatitis, acute
- Open Targets
Drugs43
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SODIUM LACTATE | CHEMBL1357 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| INDOMETHACIN | CHEMBL6 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PENTOXIFYLLINE | CHEMBL628 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PLOZASIRAN | CHEMBL6068438 | Oligonucleotide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALIPOGENE TIPARVOVEC | CHEMBL2108304 | Gene | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHYLNALTREXONE | CHEMBL1186579 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALDEMEDINE | CHEMBL2105755 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| STREPTOKINASE | CHEMBL2108147 | Enzyme | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZEGOCRACTIN | CHEMBL4753998 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 43
See all 43 drugsTargets62
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 3 | Mu opioid receptor agonist; Mu opioid receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PLG | Plasminogen | 2 | Plasminogen activator; Plasminogen inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5340 | Drugs and targets |
| ACHE | Acetylcholinesterase | 1 | Acetylcholinesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/43 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Unknown | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Unknown | https://conductscience.org/library/genes/151 | Drugs and targets |
1 to 10 of 62
See all 62 targetsTrials40
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05162014 | To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin | 494,679 | 2024-03-18 | Diabetes Mellitus, Type 2 | EMPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01077323 | A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents | 363,766 | 2010-10-06 | Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies) | EXENATIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04681066 | A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS | Phase 2 | 216 | 2025-10-16 | Acute Pancreatitis, Systemic Inflammatory Response Syndrome | ZEGOCRACTIN | Its record names the disease | ClinicalTrials.gov |
| NCT02487225 | Pentoxifylline Treatment in Acute Pancreatitis (AP) | Phase 3 | 83 | 2019-01-23 | Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis, Trauma Acute Pancreatitis, Hypertriglyceridemia Acute Pancreatitis, Idiopathic (Unknown) Acute Pancreatitis, Medication Induced Acute Pancreatitis, Cancer Acute Pancreatitis, Miscellaneous (i.e. Acute on Chronic Pancreatitis) | PENTOXIFYLLINE | Its record names the disease | ClinicalTrials.gov |
| NCT02543658 | Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension | Phase 2 | 80 | 2020-08-06 | Acute Pancreatitis, Intra-abdominal Hypertension | NEOSTIGMINE | Its record names the disease | ClinicalTrials.gov |
| NCT05089084 | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) | Phase 3 | 75 | 2026-02-04 | Familial Chylomicronemia | PLOZASIRAN | Its record names the disease | ClinicalTrials.gov |
| NCT03452228 | Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis | Phase 2 | 52 | 2023-02-16 | Severe Hypertriglyceridemia (sHTG) | EVINACUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02692391 | A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis | Phase 3 | 42 | 2021-04-22 | Acute Pancreatitis | INDOMETHACIN | Its record names the disease | ClinicalTrials.gov |
| NCT02189252 | An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis | Phase 1 | 30 | 2016-06-20 | Severe Hypertriglyceridemia | DOCONEXENT, ICOSAPENT | Its record names the disease | ClinicalTrials.gov |
| NCT01292005 | Pentoxifylline Treatment of Acute Pancreatitis | Early phase 1 | 28 | 2013-12-13 | Acute Pancreatitis | PENTOXIFYLLINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 40
See all 40 trialsComparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pentoxifylline vs Placebo: deaths from any cause | 2 of 45 | 0 of 38 | 83 | NCT02487225 | Trial comparisons |
| Pentoxifylline vs Placebo: serious adverse events | 1 of 45 | 0 of 38 | 83 | NCT02487225 | Trial comparisons |
| Neostigmine vs Conservative Treatment: Number of Participants With Adverse Effects on the Cardiovascular System | 8 of 40 | 4 of 40 | 80 | NCT02543658 | Trial comparisons |
| Neostigmine vs Conservative Treatment: New-onset Organ Failure | 12 of 40 | 16 of 40 | 80 | NCT02543658 | Trial comparisons |
| Neostigmine vs Conservative Treatment: New-onset Abdominal Compartment Syndrom | 2 of 40 | 4 of 40 | 80 | NCT02543658 | Trial comparisons |
| Neostigmine vs Conservative Treatment: Death of 90 Days | 10 of 40 | 11 of 40 | 80 | NCT02543658 | Trial comparisons |
| Neostigmine vs Conservative Treatment: Number of Participants With Deterioration of IAH | 4 of 40 | 8 of 40 | 80 | NCT02543658 | Trial comparisons |
| Neostigmine vs The Traditional Treatment: deaths from any cause | 10 of 40 | 11 of 40 | 80 | NCT02543658 | Trial comparisons |
| Neostigmine vs The Traditional Treatment: serious adverse events | 8 of 40 | 4 of 40 | 80 | NCT02543658 | Trial comparisons |
| Indomethacin Suppository vs Placebo: Mortality | 0 of 18 | 1 of 24 | 42 | NCT02692391 | Trial comparisons |
1 to 10 of 17
See all 17 comparisons in its trialsPapers from its trials25
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006515
GET https://conductscience.org/api/diseases/v1/MONDO_0006515/drugs?page=2